Earnings Presentation Materials for the Fiscal Year Ending March 2026 | Ubicom Holdings,Inc. (3937) timely disclosure

Worth reading

65In focus

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

348

¥ million (year-on-year decline in consolidated revenue)

Wording

Avoiding a definitive answer

How definitive the wording is.

Contents of this document

Financial Results PresentationFiscal year ending March 2026, full year12 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales5,992 Millions of yen-5.5%

Operating profit1,304 Millions of yen-0.9%

Ordinary income1,287 Millions of yen-4.0%

Net income891 Millions of yen+3.9%

Operating profit margin

rate_pct21.8

yoy_change_pointsUp 1.1 percentage points from 20.7% in the previous period

Full-year earnings forecast

Net Sales

7,383 Millions of yen

Operating profit

1,511 Millions of yen

Ordinary income

1,520 Millions of yen

Net income

1,056 Millions of yen

Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。

Net Sales91.2%

Operating profit96.5%

Ordinary income94.4%

Net income94.0%

What the company explained in this material

Self-assessment against the planThe company's self-assessment against its own plan.

Below the earnings forecast. However, operating profit before deducting M&A-related expenses exceeded the earnings forecast and increased from the previous period.

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Profit decline due to strategically restrained orders in the first halfDecrease of approximately ¥60 million
Expansion of direct-contract projects and cost structure reforms at the Philippine subsidiary¥82 million increase in operating profit
M&A-Related CostsAmount not disclosed

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

Expansion of the Medical Business revenue base and contributions from subsidiaries acquired through M&A
Increase in depreciation expense for MightyChecker Cloud X
Amortization of goodwill and temporary integration-related expenses associated with M&A are included
Revenue contributions from AI-driven development becoming production projects are not conservatively included
No material impact from geopolitical risks, including the situation in the Middle East, is assumed

New initiatives

Acquisition of ラジエンスウエア株式会社 as a subsidiary
Launch of the new MightyChecker Cloud X product
Establishment of an AI center in the Philippines
Development of an AI-driven development structure and promotion of PoCs and implementation
Expansion of the Insurance Knowledge Platform to life insurance companies

Key KPIsA metric the company considers important as a management benchmark.

Number of Mighty Series users22,912 facilities
Year on year against the same period last year+968 facilities
Hospital share49 Approximately %
Clinic share18 Approximately %
Mighty Series retention rate99.6 %
Number of companies using AI15 companies
Group direct-sales ratio4.8 %
LTV¥128 10,000
LTV/CAC ratio9.3 times

Unit price and quantity metricsThese figures show sales broken down by price and volume.

Number of Mighty Series users22,912 facilities
Revenue per company from the Insurance Knowledge PlatformSeveral million to tens of millions of yen
MightyChecker EX initial license fee¥54.4 10,000 15 months
MightyChecker EX monthly revenue¥3.6 10,000/month

Segment results

Medical Business

Net Sales

1,949 Millions of yen+13.1%

Operating profit

1,226 Millions of yen+8.7%

Technology Consulting Business

Net Sales

4,043 Millions of yen-12.4%

Operating profit

430 Millions of yen-23.3%

Philippine subsidiary

Net Sales

2,849 Millions of yen-2.5%

Operating profit

365 Millions of yen+28.9%

Medium-term management plan targets

M&ACumulative total of 8–10 companies from 2025 to 2030

Group direct-sales ratio35% in 2030

LTV¥1.97 million in 2030

CAC15% reduction by 2030

LTV/CAC ratio14.2x in 2030

Market Size / Share

Hospital share: approximately 49%
Clinic share: approximately 18%
Japan's small-hospital market: approximately 3,000 facilities; approximately 2,000 target facilities have not yet adopted the Mighty Series
Financial services, manufacturing, healthcare and energy accounted for 53% of the global generative AI market in 2030

Number of employees

Training has begun for approximately 50 AI-native engineers. The Group has more than 900 engineers.

Annual Dividend

Fiscal year ending March 2026

Annual¥40 per share

BreakdownStable dividend of ¥25 and performance-linked dividend of ¥15

Fiscal year ending March 2027

AnnualTo be determined

BreakdownStable dividend of ¥25; performance-linked dividend undecided at this time

Payout ratio

Fiscal year ending March 202654.4 %

PolicyA guideline of 50% or more over the medium to long term

Contents of this document
Item	Details
Document type	Financial Results Presentation
Fiscal Period Covered	Fiscal year ending March 2026, full year
Net Sales	5,992 Millions of yen (YoY -5.5%)
Operating profit	1,304 Millions of yen (YoY -0.9%)
Ordinary income	1,287 Millions of yen (YoY -4.0%)
Net income	891 Millions of yen (YoY +3.9%)
Operating profit margin	rate_pct 21.8 / yoy_change_points Up 1.1 percentage points from 20.7% in the previous period
Full-year earnings forecast	Net Sales 7,383 Millions of yen / Operating profit 1,511 Millions of yen / Ordinary income 1,520 Millions of yen / Net income 1,056 Millions of yen
Progress against full-year forecast	Net Sales 91.2% / Operating profit 96.5% / Ordinary income 94.4% / Net income 94.0%
Self-assessment against the plan	Below the earnings forecast. However, operating profit before deducting M&A-related expenses exceeded the earnings forecast and increased from the previous period.
Segment results	Medical Business Net Sales 1,949 Millions of yen (YoY +13.1%) / Operating profit 1,226 Millions of yen (YoY +8.7%) / Technology Consulting Business Net Sales 4,043 Millions of yen (YoY -12.4%) / Operating profit 430 Millions of yen (YoY -23.3%) / Philippine subsidiary Net Sales 2,849 Millions of yen (YoY -2.5%) / Operating profit 365 Millions of yen (YoY +28.9%)
Breakdown of Factors Affecting the Change	Factors Profit decline due to strategically restrained orders in the first half / Amount Decrease of approximately ¥60 million, Factors Expansion of direct-contract projects and cost structure reforms at the Philippine subsidiary / Amount ¥82 million increase in operating profit, Factors M&A-Related Costs / Amount Amount not disclosed
Key KPIs	Indicator name Number of Mighty Series users / Value 22,912 facilities / Year on year against the same period last year +968 facilities, Indicator name Hospital share / Value 49 Approximately % / Year on year against the same period last year Not disclosed, Indicator name Clinic share / Value 18 Approximately % / Year on year against the same period last year Not disclosed, Indicator name Mighty Series retention rate / Value 99.6 % / Year on year against the same period last year Not disclosed, Indicator name Number of companies using AI / Value 15 companies / Year on year against the same period last year Not disclosed, Indicator name Group direct-sales ratio / Value 4.8 % / Year on year against the same period last year Not disclosed, Indicator name LTV / Value ¥128 10,000 / Year on year against the same period last year Not disclosed, Indicator name LTV/CAC ratio / Value 9.3 times / Year on year against the same period last year Not disclosed
Unit price and quantity metrics	Indicator name Number of Mighty Series users / Value 22,912 facilities, Indicator name Revenue per company from the Insurance Knowledge Platform / Value Several million to tens of millions of yen, Indicator name MightyChecker EX initial license fee / Value ¥54.4 10,000 (15 months), Indicator name MightyChecker EX monthly revenue / Value ¥3.6 10,000/month
Number of employees	Training has begun for approximately 50 AI-native engineers. The Group has more than 900 engineers.
Assumptions Underlying the Business Outlook	Expansion of the Medical Business revenue base and contributions from subsidiaries acquired through M&A, Increase in depreciation expense for MightyChecker Cloud X, Amortization of goodwill and temporary integration-related expenses associated with M&A are included, Revenue contributions from AI-driven development becoming production projects are not conservatively included, No material impact from geopolitical risks, including the situation in the Middle East, is assumed
Medium-term management plan targets	M&A Cumulative total of 8–10 companies from 2025 to 2030 / Group direct-sales ratio 35% in 2030 / LTV ¥1.97 million in 2030 / CAC 15% reduction by 2030 / LTV/CAC ratio 14.2x in 2030
Annual Dividend	Fiscal year ending March 2026 Annual ¥40 per share / Breakdown Stable dividend of ¥25 and performance-linked dividend of ¥15 / Fiscal year ending March 2027 Annual To be determined / Breakdown Stable dividend of ¥25; performance-linked dividend undecided at this time
Payout ratio	Fiscal year ending March 2026 54.4 % / Policy A guideline of 50% or more over the medium to long term
Market Size / Share	Hospital share: approximately 49%, Clinic share: approximately 18%, Japan's small-hospital market: approximately 3,000 facilities; approximately 2,000 target facilities have not yet adopted the Mighty Series, Financial services, manufacturing, healthcare and energy accounted for 53% of the global generative AI market in 2030
New initiatives	Acquisition of ラジエンスウエア株式会社 as a subsidiary, Launch of the new MightyChecker Cloud X product, Establishment of an AI center in the Philippines, Development of an AI-driven development structure and promotion of PoCs and implementation, Expansion of the Insurance Knowledge Platform to life insurance companies

Items this document does not state (10)

Gross Profit MarginSelling, general and administrative expensesResults for the three months of the current quarterNumber of stores and locationsRisk amount incorporated into the outlookFinancial targetsAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue and profit were affected by fluctuations in revenue associated with portfolio optimization, restrained orders for small-scale, short-term and low-profitability projects in the Technology Consulting Business, the prioritization of AI engineer training, and one-time M&A-related expenses associated with the acquisition of ラジエンスウエア株式会社 as a subsidiary. In the Medical Business, the expansion of subscription revenue and M&A contributed to results, while at the Philippine subsidiary, growth in direct-contract projects and cost structure reforms contributed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.